During orthotopic liver transplantation (OLT), clamping of the portal vein induces splanchnic venous congestion and accumulation of noxious compounds. These adverse effects could increase ischemia/reperfusion injury and subsequently the risk of graft dysfunction, especially for grafts harvested from extended criteria donors (ECDs). Temporary portocaval shunt (TPCS) could prevent these complications. Between 2002 and 2013, all OLTs performed in our center were retrospectively analyzed and a propensity score matching analysis was used to compare the effect of TPCS in 686 patients (343 in each group). Patients in the TPCS group required fewer intraoperative transfusions (median number of packed red blood cells-5 versus 6; P 5 0.02; median number of fresh frozen plasma-5 versus 6; P 5 0.02); had improvement of postoperative biological parameters (prothrombin time, Factor V, international normalized ratio, alkaline phosphatase, and gammaglutamyltransferase levels); and showed significant reduction of biliary complications (4.7% versus 10.2%; P 5 0.006). Survival analysis revealed that TPCS improved 3-month graft survival (94.2% versus 88.6%; P 5 0.01) as well as longterm survival of elderly (ie, age > 70 years) donor grafts (P 5 0.02). In conclusion, the use of TPCS should be recommended especially when considering an ECD graft.
The success of orthotopic liver transplantation (OLT) has increased the waiting time for patients to receive transplantations. (1) In order to reduce the number of deaths of patients on the waiting list, transplant teams have expanded the donor pool by increasing the use of grafts harvested from extended criteria donors (ECDs). (2, 3) However, ECD grafts are known to be more vulnerable to ischemia/reperfusion injury (IRI), resulting in a higher rate of early allograft dysfunction (EAD). (4, 5) During OLT, the clamping and sectioning of the portal vein (PV) from the native liver induces splanchnic venous congestion, intestinal edema, bacterial translocation, and accumulation of noxious elements, (6, 7) which can eventually lead to graft dysfunction.
First described by Tzakis et al. in 1993 , (8) temporary portocaval shunt (TPCS) performed during the anhepatic phase of OLT with inferior vena cava (IVC) preservation, enables preservation of splanchnic blood outflow. Retrospective studies have shown that TPCS was associated with better intraoperative hemodynamic parameters, decreased incidence of reperfusion syndrome (9, 10) and better graft survival, (11) especially for ECD grafts. (12) However, these beneficial effects were not found in the only prospective randomized trial (13) in which no special attention was paid to ECD grafts. Therefore, whether TPCS is useful or not is still debated, (14, 15) and its use remains limited. (16) The aim of our study was to evaluate the interest of TPCS using a matched population analysis based on a propensity score, with special focus on ECD graft survival because we hypothesized that TPCS could reduce ECD liver graft vulnerability to IRI.
Patients and Methods

PATIENT SELECTION
All transplanted patients in our department between January 2002 and December 2013 were retrospectively analyzed ( Fig. 1) . In all cases, the graft came from a brain death donor and was usually conserved with Celsior. In order to specifically evaluate the interest of TPCS, only patients for whom the decision to perform TPCS or not depended on the surgeon's preference were included. We therefore excluded from the study patients with complete portal vein thrombosis (PVT) associated with portal cavernoma (n 5 10) because these patients could not possibly have TPCS as well as patients who had permanent surgical portocaval shunt prior to transplantation (n 5 5). We also excluded patients transplanted for acute liver failure (n 5 41) because TPCS was always performed for these patients. Ultimately, the patients transplanted with a split graft (n 5 39) or a living donor graft (n 5 4) and retransplanted patients (n 5 126) were also excluded because their outcomes were at significantly higher risk regardless of the use of TPCS or not. This retrospective study received approval from the local ethical committee.
SURGICAL PROCEDURE AND MEDICAL CARE
All of the patients had OLT with IVC preservation. Briefly, after standard wound incision and exposition, the hepatoduodenal ligament was first dissected with PV divided prior to liver mobilization. Therefore, according to the surgeon's habits, a TPCS (ie, endto-side running suture between the anterior surface of the suprarenal IVC and the PV) was performed or not. Indeed, some surgeons are used to systematically performed TPCS whereas others would never perform it, regardless of recipient's characteristic (ie, degree of portal hypertension or history of liver surgery).
The native liver was then removed and careful hemostasis was performed. Graft implantation started with a side-to-side caval anastomosis. (17) When performed, the TPCS was then ligated distally with vascular stapler. PV anastomosis was performed end-toend. The graft was then vascularized prior to artery and then biliary anastomosis. The biliary reconstruction was usually a duct-to-duct anastomosis between the 2 main bile ducts, except in case of transplantation for sclerosing cholangitis or perihilar cholangiocarcinoma (which systematically required a hepaticojejunostomy). Biliary drainage was done according to surgeon preference.
After the procedure, patients were transferred to the intensive care unit (ICU) until graft function was satisfactory. Routine immunosuppression usually associated low-dose calcineurin inhibitor with mycophenolate mofetil, and a short course of corticosteroids. (18) No significant modification regarding the surgical procedure or the postoperative medical care was observed during the study period.
CLINICAL AND BIOLOGICAL PARAMETER DEFINITIONS
Clinical and biological data were retrospectively gathered from a prospective database. The following parameters were analyzed: donor and recipient demographics, underlying liver disease and OLT indication, Child-Pugh and Model for End-Stage Liver Disease (MELD) scores (retrospectively calculated for patients transplanted before 2007, date at which a MELD score-based graft allocation system was instituted in France), cold ischemia time, intraoperative transfusion (packed red blood cells, fresh frozen plasma, and platelet count), posttransplant liver and renal function (estimated by Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] value), (19) arterial complications (ie, thrombosis and stenosis), and biliary complications (ie, biliary leakage and stenosis).
An extended criteria graft was considered when the donor matched at least 1 of the following criteria: age > 65 years; body mass index (BMI) > 30 kg/m (2) ; ICU stay > 7 days prior to harvesting; natremia > 155 mmol/L; and liver enzymes 3 times higher than the normal value, ie, aspartate aminotransferase (ASAT) blood level > 150 IU/mL, alanine aminotransferase (ALAT) blood level > 170 IU/mL. EAD was defined according to Olthoff et al. (20) criteria (ie, presence of 1 or more of the following criteria: bilirubin level 10 mg/dL on postoperative day [POD] 7; international normalized ratio [INR] 1.6 on POD 7; ALAT or ASAT level > 2000 IU/L within the 7 POD).
Patient and graft survival at 3 and 12 months and overall survival were calculated.
STATISTICAL ANALYSIS AND PROPENSITY SCORE MATCHING
In order to minimize bias because of the heterogeneity of recipient or graft characteristics, we performed propensity score matching (1:1 ratio). The variables included in the calculation of the propensity score were as follows: recipient age, sex, indication for transplantation (included as factorial variable), MELD score, Child-Pugh grade, and use of ECD grafts. Exact match was prioritized and the maximum distance allowed between 2 matched patients was set at 0.1 (ie, caliper restriction).
Quantitative variables were expressed as mean 6 standard deviation or by median with extreme values and compared using Student t test or Wilcoxon test as appropriate. Qualitative variables were expressed as number and percentage and compared using a chi-square or Fisher's exact test, as appropriate.
Survival analysis was made with Kaplan-Meier curve and compared with log-rank test. Analysis and comparison of longitudinal data (ie, evolution of biological parameters during postoperative time) was made with a linear mixed model with random intercept. (21) A P < 0.05 value was considered to be statistically significant.
All statistical analyses were made with R software, version 3.1.3 (www.r-project.org). The matching procedure was performed with the "Matching" package version 4.9-2. The linear mixed model was made and analyzed with the "nlme" package version 3.1.
Results
PROPENSITY SCORE MATCHING PROCEDURE
A total of 954 patients were analyzed among whom 567 patients had TPCS and 387 patients did not. Because of missing data, propensity scores could only be calculated for 830 patients: 480 who had TPCS and 350 who did not. After the matching procedure, 7 patients did not have appropriate matching due to the caliper restriction. Finally, 343 patients in the TPCS group were matched with 343 patients in the non-TPCS group (Fig. 1) . No statistical difference was found between the 2 groups regarding demographic or preoperative data (Table 1) .
IMPACT OF TPCS ON INTRAOPERATIVE AND POSTOPERATIVE COURSE
Intraoperative Parameters
Cold ischemia time was similar in the 2 groups, although the duration of the procedure was significantly higher in the TPCS group compared with the non-TPCS group (388.5 versus 362 minutes; P 5 0.03) as well as anhepatic duration (120 versus 102 minutes; P 5 0.001; Table 2 ).
The median number of intraoperative transfusions was significantly lower in the TPCS group versus the non-TPCS group regarding packed red blood cells (5 [range, 0-36] versus 6 [range, 0-40]; P 5 0.02) as well as fresh frozen plasma (5 [range, 0-37] versus 6 [range, 0-40]; P 5 0.02). There were also more patients in the TPCS group requiring no transfusion of packed red blood cells (20.1% versus 12.8%; P 5 0.01) or of fresh frozen plasma (21.0% versus 14.6%; P 5 0.04). However, there was no significant difference regarding platelet count transfusion.
Postoperative Course
There was no significant difference between the 2 groups regarding postoperative ASAT (P 5 0.20) and ALAT (P 5 0.38) levels (Fig. 2) . However, the INR and prothrombin time were significantly improved (P 5 0.047 and P 5 0.04, respectively) in the TPCS group although it nearly reached significance for Factor V (FV) level (P 5 0.09; Fig. 3 ). Incidence of biliary complications was also significantly lower in the TPCS group compared with the non-TPCS group (4.7% versus 10.2%, respectively; P 5 0.006), resulting in an improvement of alkaline phosphatase (ALP) level (P < 0.001) and gamma-glutamyltransferase (GGT) level (P 5 0.07) in the TPCS group. However, postoperative bilirubin level was similar between the 2 groups (P 5 0.53; Fig. 4 ). There was no difference between the TPCS and the non-TPCS groups regarding the incidence of arterial complications (10.8% versus 11.1%, respectively; P > 0.99), rate of EAD (21.9% versus 23.0%; 
SURVIVAL ANALYSIS
The 3-month graft survival rate was significantly improved in the TPCS group compared with the non-TPCS group (94.2% versus 88.6%; P 5 0.01), especially when considering the subgroup of patients transplanted with ECD grafts (95.2% versus 89.0%; P 5 0.04), although this difference did not reach significance in the subgroup of patients transplanted with NOTE: Data are given as n (%) or median (range). *Reported only for duct-to-duct anastomosis.
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non-ECD grafts (92.9% versus 88.2%; P 5 0.23). The main causes of 3-month graft losses are reported in Table 3 .
Regarding the overall graft survival, there was no significant difference (P 5 0.21) between the 2 groups (Fig. 5A ) even when specifically considering ECD grafts (P 5 0.31; Fig. 5B ). However, subgroup analysis revealed that TPCS significantly improved overall graft survival from elderly (age > 70 years) donors (P 5 0.02; Fig. 6 ). 
FIG. 2. Evolution of aminotransferase levels in the early
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Discussion
OLT is the most effective treatment for end-stage liver diseases. Because of the limited number of donors, this success has led to an increase in the discrepancy between the number of candidates and transplanted patients and has forced transplant teams to increase the use of ECD grafts. This strategy has reduced the deaths of patients on waiting lists (22) but has increased the rate of graft dysfunction. (5) Our study aimed at evaluating if TPCS, performed during the anhepatic phase of the transplant procedure, could improve graft function and survival. Using a propensity score matching analysis, we showed that TPCS significantly improved ECD graft survival in the early postoperative outcomes represented by a significant improvement of the 3-month survival rate. Moreover, this beneficial effect was even more pronounced when considering the subgroup of elderly grafts (ie, > 70 years) with an improved longterm survival in the TPCS group.
Liver parenchymal injuries related to IRI, which could be represented by transaminase levels in the early POD, were not improved by the use of TPCS. However, the incidence of biliary complications and cholestasis enzymes were significantly reduced in the TPCS group during the postoperative course, which could reflect the reduction of IRI injury in the biliary tree. We also found that TPCS significantly reduced intraoperative transfusions and improved postoperative liver function. However, this effect only prevailed in the early POD and faded progressively since POD 3, which could explain the similar rate of EAD observed between the 2 groups because the definition of EAD is based on biological parameters that are collected on POD 7 for the most part. These observations revealed that TPCS only improves initial graft recovery and its effects may then disappear due to the potential incidence of other complications (ie, immunologic, infectious, and vascular complications). We found a significant increase in operative time, which could be explained by the additional time required for performing and removing the TPCS. Even if this impact is moderate compared to the average 6 hours of the procedure, our findings and explication are questionable because TPCS could make native liver removal easier and then could reduce operative time as previously reported. (23) During OLT, the clamping and sectioning of the PV from the native liver induces portal hypertension and splanchnic venous congestion, (7) which leads to intestinal edema and mucosal barrier dysfunction, with subsequent bacterial translocation, endotoxemia, and secretion of proinflammatory cytokines (interleukin 6, tumor necrosis factor a). (8) This accumulation of noxious products is directly released into the graft on revascularization, resulting in activation of Kupffer cells and thereby exacerbating IRI lesions, (24) especially because endotoxemia clearance, which is supported by the liver, is not functional in the early period after OLT. (25) By avoiding portal hypertension during the anhepatic phase, TPCS could enable significant reduction in blood transfusion. By the same mechanism, it could reduce the production of cytotoxic elements and provide a better and safer hemodynamic situation after revascularization. (10) We believe that taken together, these phenomenon participate in improving initial graft function and survival, especially in ECD grafts which are known to be more vulnerable to hemodynamic status and IRI lesions. (26) The interest of TPCS has been previously studied by Figueras et al. (13) in the only prospective randomized study on the subject. They found an improvement of cardiac output, renal function, and reduced blood transfusion in the TPCS group especially for patients with severe portal hypertension prior to LT. However, that study failed to show an improvement in graft function in the TPCS group, probably due to the limited sample size (40 patients in each group) with almost no ECD grafts. Other studies have confirmed the benefit of TPCS on blood transfusion, intraoperative hemodynamic status, and reduction of reperfusion syndrome incidence. (10, 23, (27) (28) (29) As for graft outcome and function, Ghinolfi et al. (11) reported their series of 148 OLTs and found a significant reduction in 30-day mortality in the TPCS group and in 3-month mortality when the patients received high-risk donor grafts. However, improvement in graft function was not demonstrated. Pratschke et al. (12) also found that TPCS, using a prosthetic shunt between the portal and femoral veins, significantly reduced liver enzyme level on PODs 1, 2, and 7 as well as bilirubin level on POD 1 and significantly improved graft survival. However, despite a large study population (448 OLTs) over a 13-year study period, these results suffered from the absence of a selection process. Indeed, the patients in the shunt group were significantly younger (P < 0.001), had lower MELD scores (P 5 0.1), and had fewer emergency transplantations (P 5 0.05).
With more than 600 matched patients, our study is the largest to evaluate the benefit of TPCS. The size of the study population and the use of advanced statistical methods (ie, propensity matched analysis with a caliper restriction of 0.1 and linear mixed model) highly reduced bias because of heterogeneity of the study population and therefore enhanced the strength of our results.
However, our results must be interpreted with caution because this is a retrospective study with potential bias. Indeed, the decision to perform or not perform TPCS, which was dependent on the surgeon's habits, could still have induced a selection bias despite the matching process. Moreover, in our study, the PV was divided prior to liver mobilization in all cases although it could have been done later (ie, just before liver removal) in the non-TPCS group in order to reduce splanchnic congestion duration and then occurrence of IRI. However, most authors reported the same procedure as us. (9, 11, 13) Indeed, delaying the PV division may make the liver mobilization, the detachment of the caudate lobe from the IVC, and the section of the retrohepatic accessory veins harder and consequently increase bleeding during the liver mobilization. Therefore, our results must be confirmed by a prospective randomized trial with enough power. This awaited study (29) is currently being performed by our team (clinical trial: NCT02784119).
In conclusion, during OLT, TPCS should be recommended especially when considering the use of an ECD graft which now represents the majority of situations. These results should be confirmed by a prospective randomized trial.
